ES2177579T3 - Solucion acuosa de factor viii de bajo contenido en oxigeno. - Google Patents

Solucion acuosa de factor viii de bajo contenido en oxigeno.

Info

Publication number
ES2177579T3
ES2177579T3 ES94915307T ES94915307T ES2177579T3 ES 2177579 T3 ES2177579 T3 ES 2177579T3 ES 94915307 T ES94915307 T ES 94915307T ES 94915307 T ES94915307 T ES 94915307T ES 2177579 T3 ES2177579 T3 ES 2177579T3
Authority
ES
Spain
Prior art keywords
factor viii
oxygen
activity
water solution
solution contained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94915307T
Other languages
English (en)
Inventor
Thomas Osterberg
Angelica Fatouros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum AB filed Critical Biovitrum AB
Application granted granted Critical
Publication of ES2177579T3 publication Critical patent/ES2177579T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN FARMACO FINAL QUE CONTIENE UN FACTOR DE COAGULACION VIII EN UNA SOLUCION ACUOSA CON UNA CONCENTRACION REDUCIDA DE OXIGENO. DE ESTE MODO, LA ACTIVIDAD DEL FACTOR VIII SE PUEDE RETENER DURANTE SU ALMACENAMIENTO HASTA UN GRADO SORPRENDENTEMENTE ALTO. LA ACTIVIDAD DEL FACTOR VIII SE PUEDE RETENER DURANTE UN PERIODO PROLONGADO DE TIEMPO SI EL FARMACO FINAL CONTIENE ADEMAS UN GAS INERTE Y/O UN ANTIOXIDANTE. LA PRESENTE INVENCION TAMBIEN SE REFIERE A PROCESOS PARA REDUCIR LA CONCENTRACION DE OXIGENO DE LA SOLUCION ACUOSA Y A UN METODO PARA MEJORAR LA ESTABILIDAD DEL FACTOR VIII EN UNA SOLUCION ACUOSA MEDIANTE EL ALMACENAMIENTO DE LA SOLUCION BAJO UNA ATMOSFERA DE GAS INERTE. CON LA PRESENTE INVENCION SE PUEDE RETENER AL MENOS UN 50% DE LA ACTIVIDAD INICIAL DEL FACTOR VIII TRAS EL ALMACENAMIENTO DURANTE AL MENOS 6 MESES A UNA TEMPERATURA DE 2 A 10 (GRADOS) C Y A UN PH DE LA SOLUCION DE 6,5 A 8,5.
ES94915307T 1993-05-07 1994-03-24 Solucion acuosa de factor viii de bajo contenido en oxigeno. Expired - Lifetime ES2177579T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939301581A SE9301581D0 (sv) 1993-05-07 1993-05-07 Protein formulation

Publications (1)

Publication Number Publication Date
ES2177579T3 true ES2177579T3 (es) 2002-12-16

Family

ID=20389868

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94915307T Expired - Lifetime ES2177579T3 (es) 1993-05-07 1994-03-24 Solucion acuosa de factor viii de bajo contenido en oxigeno.

Country Status (24)

Country Link
US (1) US5962650A (es)
EP (1) EP0700299B1 (es)
JP (1) JP3751633B2 (es)
KR (1) KR100304143B1 (es)
CN (1) CN1113655C (es)
AT (1) ATE218354T1 (es)
AU (1) AU681883B2 (es)
CA (1) CA2161350C (es)
CZ (1) CZ293527B6 (es)
DE (1) DE69430745T2 (es)
DK (1) DK0700299T3 (es)
EE (1) EE03118B1 (es)
ES (1) ES2177579T3 (es)
FI (1) FI111910B (es)
HU (1) HU215263B (es)
NO (1) NO321769B1 (es)
NZ (1) NZ266031A (es)
PL (1) PL174866B1 (es)
PT (1) PT700299E (es)
RU (1) RU2142290C1 (es)
SE (1) SE9301581D0 (es)
SK (1) SK283002B6 (es)
WO (1) WO1994026286A1 (es)
ZA (1) ZA942251B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5929031A (en) * 1995-05-02 1999-07-27 Baxter Biotech Technology Sarl Storage stable hemoglobin solutions
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
DK1820516T3 (da) * 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
DE60024268T2 (de) * 1999-07-13 2006-08-03 Biovitrum Ab Zusammensetzungen mit stabilem faktor viii
JP3466516B2 (ja) * 1999-09-07 2003-11-10 科学技術振興事業団 安定保存可能な酸素輸液剤
EP1458408B1 (en) * 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
AU2002351755A1 (en) * 2001-12-21 2003-07-15 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN1671410B (zh) * 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
RU2364609C2 (ru) 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
EP1641487B1 (en) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
CN1917861B (zh) * 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
DK1750733T3 (da) * 2004-05-03 2014-01-20 Univ Emory FREMGANGSMÅDE TIL INDGIVELSE AF SVINE-B-DOMÆNELØS fVIII
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
US7504377B2 (en) 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
ATE471158T1 (de) * 2007-04-17 2010-07-15 Schwabe Willmar Gmbh & Co Verfahren zur herstellung von lagerstabilen lösungen aus pelargonium-extrakten
CN101730707B (zh) * 2007-07-11 2014-12-17 诺沃-诺迪斯克有限公司 使用混合式或多模式树脂来纯化因子ⅷ
EP2113564A1 (en) 2008-05-01 2009-11-04 Arecor Limited Protein formulation
MX2011001624A (es) 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
WO2010026186A1 (en) * 2008-09-03 2010-03-11 Octapharma Ag New protecting compositions for recombinantly produced factor viii
MX339060B (es) 2008-11-07 2016-05-09 Baxter Int Formulaciones del factor viii.
NO2440239T3 (es) 2009-06-09 2018-02-10
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
US12089589B2 (en) 2009-10-12 2024-09-17 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
US9339025B2 (en) 2010-08-25 2016-05-17 New Health Sciences, Inc. Method for enhancing red blood cell quality and survival during storage
PT2635114T (pt) 2010-11-05 2020-06-16 New Health Sciences Inc Irradiação de glóbulos vermelhos e armazenamento anaeróbico
DK2635297T3 (da) 2010-11-05 2019-05-06 Baxalta GmbH En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
ES2984863T3 (es) 2011-08-10 2024-10-31 Hemanext Inc Dispositivo integrado de filtrado de leucocitos, oxígeno y/o agotamiento de CO2, y separación de plasma
ES2900298T3 (es) 2013-02-28 2022-03-16 Hemanext Inc Dispositivo de agotamiento de gas para productos sanguíneos
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
PT3970731T (pt) 2015-03-10 2026-02-24 Hemanext Inc Kits descartáveis de redução de oxigénio, dispositivos e métodos de utilização dos mesmos
WO2016172645A1 (en) 2015-04-23 2016-10-27 New Health Sciences, Inc. Anaerobic blood storage containers
CA2985799A1 (en) 2015-05-18 2016-11-24 New Health Sciences, Inc. Methods for the storage of whole blood, and compositions thereof
KR20240132129A (ko) 2016-05-27 2024-09-02 헤마넥스트 인코포레이티드 혐기성 혈액 저장 및 병원체 불활성화 방법
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2896381A (en) * 1954-05-27 1959-07-28 Hodes Lange Corp Method and apparatus for treating and filling ampoules
US3143471A (en) * 1962-01-18 1964-08-04 Merck & Co Inc Argon method of drying and preserving lyophilized therapeutic products
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
EP0081482A1 (en) * 1981-06-18 1983-06-22 E. G. Birger Blombäck A process in purification and concentration of the factor viii complex
DE3144705C2 (de) * 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4727027A (en) * 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
EP0212040B1 (de) * 1985-08-05 1990-05-23 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Herstellung von Präparationen auf Basis von Blutgerinnungsfaktoren
US4709819A (en) * 1986-07-23 1987-12-01 Environmental Diagnostics, Inc. Method for preserving plated media and product
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DK18288D0 (da) * 1988-01-15 1988-01-15 Nordisk Gentofte Fremgangsmaade til pasteurisering af vandige oploesninger af faktor viii
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
GB8808810D0 (en) * 1988-04-14 1988-05-18 Biopharm Clinical Research Ltd Heparin-containing formulations
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
TW211015B (es) * 1990-01-11 1993-08-11 Nippon Shinyaku Co Ltd
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
EP0789612B1 (en) * 1994-10-31 2002-09-04 Kimberly-Clark Worldwide, Inc. High density nonwoven filter media

Also Published As

Publication number Publication date
NO954457D0 (no) 1995-11-07
PT700299E (pt) 2002-11-29
NO954457L (no) 1995-11-07
DE69430745D1 (de) 2002-07-11
DE69430745T2 (de) 2002-10-17
HU215263B (hu) 1998-11-30
CN1113655C (zh) 2003-07-09
KR960702317A (ko) 1996-04-27
US5962650A (en) 1999-10-05
DK0700299T3 (da) 2002-09-23
HUT73693A (en) 1996-09-30
CA2161350A1 (en) 1994-11-24
JPH08509745A (ja) 1996-10-15
KR100304143B1 (ko) 2001-11-22
CA2161350C (en) 2007-10-30
EE03118B1 (et) 1998-10-15
FI955305A0 (fi) 1995-11-06
NO321769B1 (no) 2006-07-03
PL311567A1 (en) 1996-02-19
PL174866B1 (pl) 1998-09-30
CZ293527B6 (cs) 2004-05-12
ATE218354T1 (de) 2002-06-15
CN1122573A (zh) 1996-05-15
AU681883B2 (en) 1997-09-11
WO1994026286A1 (en) 1994-11-24
SK138395A3 (en) 1997-02-05
FI955305L (fi) 1995-11-06
SK283002B6 (sk) 2003-01-09
NZ266031A (en) 1997-04-24
EP0700299A1 (en) 1996-03-13
HU9503171D0 (en) 1996-01-29
EP0700299B1 (en) 2002-06-05
JP3751633B2 (ja) 2006-03-01
SE9301581D0 (sv) 1993-05-07
ZA942251B (en) 1994-11-01
RU2142290C1 (ru) 1999-12-10
FI111910B (fi) 2003-10-15
CZ286995A3 (en) 1996-05-15
AU6659794A (en) 1994-12-12

Similar Documents

Publication Publication Date Title
ES2177579T3 (es) Solucion acuosa de factor viii de bajo contenido en oxigeno.
SG46496A1 (en) Tricyclopolyazamacrocyclophosphonic acids complexes and derivatives thereof for use as constrast agents
ATE158918T1 (de) Konservierungslösung für zellen
CA2075060A1 (en) Novel vehicle gases and their use in medical preparations
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
ATE151620T1 (de) Gefässimplantat
ATE280150T1 (de) Verfahren zur herstellung von mono-langkettigen aminoxid tensiden mit niedrigem nitrit-, nitrosamin- und restperoxid-gehalt
ES2071292T3 (es) Soluciones inyectables estables de factor viii.
AU3369299A (en) Stable concentrated rare earth carboxylate liquids
DE69630291D1 (de) Proteinformulierung, die koajulationsfehler viii oder ix in einer saccharose wässriger lösung enthält
DE3266087D1 (en) Cysteine delivery system
BR0213298A (pt) formulações com alta concentração de proteìna e processo de fabricação
KR950005986A (ko) 안정화된 형태로 금속 프로테아제 효소를 사용, 저장 및 이송하는 방법
DE60021590D1 (de) Verwendung von baclofen zur behandlung von alkoholismus
Katz Anhydrous hydrogen fluoride as a solvent for proteins and some other biologically important substances
ATE451109T1 (de) Medizinische lösung; verfahren zur herstellung dieser lösung und ihre verwendung
GB1476883A (en) Oxygenation of water
MX9603631A (es) Formulaciones liquidas, estables en almacenamiento, de aclaradores.
SE9402119D0 (sv) Solution
JPS57128635A (en) Pharmaceutical preparation of gamma-globulin for venoclysis
ES2098181A1 (es) Procedimiento para la obtencion de mercurio metal a partir de productos que contienen cloruro mercurioso.
TW332199B (en) Process for the preparation of 3-chloropropionic acid
JPS6463342A (en) Stabilization of glutathione-containing composition
DE3881471D1 (de) Oxethylsulfonyl-nitro- bzw. -amino-benzoesaeuren und verfahren zu ihrer herstellung.
JPS52146050A (en) Process for waste water with high concentration of organic component